Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2506-2514

  Jiralerspong, S ^a,b   Kim, E S ^b,c   Dong, W ^b   Feng, L ^b   Hortobagyi, G N ^b   Giordano, S H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Body mass index; Breast cancer; Diabetes; Obesity; Prognosis; Survival outcomes

Indexed keywords

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

BODY MASS INDEX; BREAST CANCER; DIABETES; OBESITY; PROGNOSIS; SURVIVAL OUTCOMES;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY COMPOSITION; BODY MASS INDEX; BREAST NEOPLASMS; BRIDGED COMPOUNDS; COHORT STUDIES; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OBESITY; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL; TAMOXIFEN; TAXOIDS; TREATMENT OUTCOME;

EID: 84884730076     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt224     Document Type: Article

References (35)

1. Flegal KM, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. van den Brandt PA, Spiegelman D, Yaun SS et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-527.
3. Trentham-Dietz A, Newcomb PA, Storer BE et al. Body size and risk of breast cancer. Am J Epidemiol 1997; 145: 1011-1019.
4. Key TJ, Appleby PN, Reeves GK et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-1226.
5. Ewertz M, Jensen MB, Gunnarsdottir KA et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29: 25-31.
6. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 2011; 29: 4-7.
7. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20: 1128-1143.
8. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat 1990; 16: 205-214.
9. Centers for Disease Control and Prevention NCfHS, Division of Health Interview Statistics, data from the National Health Interview Survey. Percentage of Civilian, Noninstitutionalized Population with Diagnosed Diabetes, by Age, United States, 1980-2008. In 2011.
10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
11. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-2764.
12. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011; 29: 7-10.
13. Peairs KS, Barone BB, Snyder CF et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
14. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
15. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
16. Dignam JJ, Wieand K, Johnson KA et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003; 95: 1467-1476.
17. Berclaz G, Li S, Price KN et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15: 875-884.
18. de Azambuja E, McCaskill-Stevens W, Francis P et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010; 119: 145-153.
19. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123: 627-635.
20. Chang VW, Asch DA, Werner RM. Quality of care among obese patients. JAMA 2010; 303: 1274-1281.
21. Kerlikowske K, Walker R, Miglioretti DL et al. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst 2008; 100: 1724-1733.
22. Maruthur NM, Bolen S, Brancati FL et al. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med 2009; 24: 665-677.
23. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-1273.
24. Griggs JJ, Mangu PB, Anderson H et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553-1561.
25. Sparano JA, Wang M, Zhao F et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012; 118: 5937-5946.
26. Sestak I, Distler W, Forbes JF et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28: 3411-3415.
27. Simpson ER, Brown KA. Minireview: obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol 2013; 27: 715-725.
28. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2012; 17: 251-261.
29. Niraula S, Ocana A, Ennis M et al. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012; 134: 769-781.
30. Sendur M, Aksoy S, Zengin N et al. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer 2012; 107: 1815-1819.
31. Pfeiler G, Konigsberg R, Fesl C et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29: 2653-2659.
32. Srokowski TP, Fang S, Hortobagyi GN et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009; 27: 2170-2176.
33. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
34. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2: 778-790.
35. Dowling RJ, Niraula S, Stambolic V et al. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48: R31-43.